<PAGE> 1
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 31, 1996
REGISTRATION NO. 333-
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------------
FORM SB-2
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933
------------------------
BIOSOURCE INTERNATIONAL, INC.
(NAME OF SMALL BUSINESS ISSUER IN ITS CHARTER)
<TABLE>
<S> <C> <C>
DELAWARE 2835 77-0340829
(State or Other Jurisdiction of (Primary Standard Industrial (I.R.S. Employer
Incorporation or Organization) Classification Code Number) Identification No.)
</TABLE>
820 FLYNN ROAD
CAMARILLO, CALIFORNIA 93012
(805) 987-0086
(Address and Telephone Number of Principal Executive Offices)
------------------------
820 FLYNN ROAD
CAMARILLO, CALIFORNIA 93012
(805) 987-0086
(Address of Principal Place of Business or Intended Principal Place of Business)
------------------------
JAMES H. CHAMBERLAIN
CHIEF EXECUTIVE OFFICER AND PRESIDENT
BIOSOURCE INTERNATIONAL, INC.
820 FLYNN ROAD
CAMARILLO, CALIFORNIA 93012
(805) 987-0086
(Name, Address and Telephone Number of Agent for Service)
------------------------
Copies to:
<TABLE>
<S> <C>
SCOTT W. ALDERTON, ESQ. MARK A. KLEIN, ESQ.
LINDA M. GIUNTA, ESQ. KATHERINE J. BLAIR, ESQ.
TROOP MEISINGER STEUBER & PASICH, LLP FRESHMAN, MARANTZ, ORLANSKI, COOPER & KLEIN
10940 Wilshire Boulevard Eighth Floor, East Tower
Los Angeles, California 90024 9100 Wilshire Boulevard
(310) 824-7000 Beverly Hills, California 90212
(310) 273-1870
</TABLE>
------------------------
APPROXIMATE DATE OF PROPOSED SALE TO THE PUBLIC:
As soon as practicable after the effective date of this Registration Statement.
------------------------
If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, please check the following box
and list the Securities Act registration statement number of the earlier
effective registration statement for the same offering. /X/
If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement
for the same offering. / /
If delivery of the prospectus is expected to be made pursuant to Rule 434,
please check the following box. / /
------------------------
CALCULATION OF REGISTRATION FEE
<TABLE>
- --------------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------------------------------
PROPOSED MAXIMUM PROPOSED MAXIMUM
TITLE OF EACH CLASS OF DOLLAR AMOUNT OFFERING PRICE AGGREGATE OFFERING AMOUNT OF
SECURITIES TO BE REGISTERED TO BE REGISTERED PER UNIT(1) PRICE(1) REGISTRATION FEE
- --------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C>
Common Stock, par value $.001 per
share............................... 315,753 Shares $9.75 $3,078,592 $1,062
- --------------------------------------------------------------------------------------------------------------------------
- --------------------------------------------------------------------------------------------------------------------------
</TABLE>
(1) Estimated solely for the purpose of calculating the registration fee
pursuant to Rule 457(c), and based on the average of the high and low bid
prices of the Common Stock on the Nasdaq National Market on May 29, 1996.
------------------------
THE REGISTRANT HEREBY AMENDS THIS REGISTRATION STATEMENT ON SUCH DATE OR
DATES AS MAY BE NECESSARY TO DELAY ITS EFFECTIVE DATE UNTIL THE REGISTRANT SHALL
FILE A FURTHER AMENDMENT WHICH SPECIFICALLY STATES THAT THIS REGISTRATION
STATEMENT SHALL THEREAFTER BECOME EFFECTIVE IN ACCORDANCE WITH SECTION 8(A) OF
THE SECURITIES ACT OF 1933 OR UNTIL THE REGISTRATION STATEMENT SHALL BECOME
EFFECTIVE ON SUCH DATE AS THE SECURITIES AND EXCHANGE COMMISSION, ACTING
PURSUANT TO SAID SECTION 8(A), MAY DETERMINE.
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE> 2
The contents of the Registration Statement on Form SB-2 (Registration No.
333-3336), registering 2,572,500 shares of common stock, $.001 par value, of
BioSource International, Inc. filed on April 10, 1996 with the Commission as
amended by Pre-Effective Amendments Nos. 1, 2 and 3, are hereby incorporated by
reference herein. Filed as exhibits hereto are the following opinions and
consents:
<TABLE>
<CAPTION>
EXHIBIT TITLE
- ------- -----
<C> <S>
5.1 Opinion of Troop Meisinger Steuber & Pasich, LLP
23.1 Consent of Independent Auditors
23.2 Consent of Independent Auditors
23.3 Consent of Troop Meisinger Steuber & Pasich, LLP (Reference is made to Exhibit 5.1)
</TABLE>
<PAGE> 3
SIGNATURES
In accordance with the requirements of the Securities Act of 1933, the
Registrant certifies that it has reasonable grounds to believe that it meets all
of the requirements for filing on Form SB-2 and authorized this Registration
Statement to be signed on its behalf by the undersigned, thereunto duly
authorized, in the City of Camarillo, State of California, on May 31, 1996.
BIOSOURCE INTERNATIONAL, INC.
By: /s/ JAMES H. CHAMBERLAIN
-----------------------------------
James H. Chamberlain
Chairman of the Board, President,
and Chief Executive Officer
In accordance with the requirements of the Securities Act of 1933, this
Registration Statement has been signed by the following persons in the
capacities and on the dates stated.
<TABLE>
<CAPTION>
SIGNATURE TITLE DATE
--------- ----- ----
<C> <S> <C>
/s/ JAMES H. CHAMBERLAIN Chairman of the Board, President May 31, 1996
- --------------------------------------------- and Chief Executive Officer,
James H. Chamberlain (Principal Executive Officer)
* Chief Financial Officer May 31, 1996
- --------------------------------------------- (Principal Accounting Officer)
Anna M. Anderson (Principal Financial Officer)
* Director May 31, 1996
- ---------------------------------------------
Leonard M. Hendrickson
* Director May 31, 1996
- ---------------------------------------------
David J. Moffa
* Director May 31, 1996
- ---------------------------------------------
John R. Overturf, Jr.
* Director May 31, 1996
- ---------------------------------------------
Robert D. Weist
*By: /s/ JAMES H. CHAMBERLAIN
- ---------------------------------------------
James H. Chamberlain
Attorney-in-Fact
</TABLE>
II-1
<PAGE> 1
EXHIBIT 5.1
[TROOP MEISINGER STEUBER & PASICH, LLP LETTERHEAD]
May 23, 1996
BioSource International, Inc.
820 Flynn Road
Camarillo, California 93012
Ladies and Gentlemen:
At your request, we have examined the Registration Statement on Form
SB-2 to be filed by BioSource International, Inc., a Delaware corporation (the
"Company"), with the Securities and Exchange Commission on May 31, 1996 (the
"Registration Statement"), in order to register under the Securities Act of
1933, up to 315,753 shares of the Common Stock, par value $0.001 per share, of
the Company (the "Shares").
We are of the opinion that the Shares have been duly authorized and,
upon issuance in conformity with and pursuant to the Registration Statement, and
receipt by the Company of the purchase price therefor as specified in the
Registration Statement, the Shares will be legally and validly issued, fully
paid and non-assessable.
We consent to the inclusion in this Registration Statement on Form SB-2
of this opinion and to the reference to our firm under the caption "Legal
Matters."
Respectfully submitted,
/s/ Troop Meisinger Steuber & Pasich, LLP
TROOP MEISINGER STEUBER & PASICH, LLP
<PAGE> 1
EXHIBIT 23.1
The Board of Directors and Stockholders
BioSource International, Inc.:
We consent to the use of our report dated February 9, 1996 included herein
relating to the consolidated balance sheet of BioSource International, Inc. and
subsidiary as of December 31, 1995 and the related consolidated statements of
operations, stockholders' equity and cash flows for each of the years in the
two-year period ended December 31, 1995, and to the reference to our firm under
the headings "Selected Consolidated Financial Data", and "Experts" in the
prospectus.
KPMG PEAT MARWICK LLP
Los Angeles, California
May 30, 1996
<PAGE> 1
EXHIBIT 23.2
The Board of Directors
Medgenix Diagnostics, S.A.:
We consent to the use of our report dated May 23, 1996 included herein
relating to the consolidated balance sheet of the in vitro business segment of
Medgenix Diagnostics, S.A. and subsidiaries as of October 31, 1995, and the
related consolidated statements of operations, changes in net assets and cash
flows for the years ended October 31, 1994 and 1995, and to the reference to our
firm under the heading "Experts" in the prospectus.
KPMG Reviseurs d'Entreprises
Brussels
May 30, 1996
